scholarly journals 965: EFFICACY AND SAFETY OF PHENOBARBITAL IN ACUTE ALCOHOL WITHDRAWAL SYNDROME: A RETROSPECTIVE ANALYSIS

2021 ◽  
Vol 50 (1) ◽  
pp. 479-479
Author(s):  
Marjorie Peck ◽  
Joe Bodkin ◽  
A. Katie Hiles ◽  
David Reeves ◽  
Ross E. Heskett
Keyword(s):  
Retrospective Analysis ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Alcohol Withdrawal Syndrome ◽  
Efficacy And Safety

scholarly journals Efficacy and Safety of Pregabalin in the Treatment of Alcohol Withdrawal Syndrome: A Randomized Placebo-Controlled Trial

2012 ◽  
Vol 47 (2) ◽  
pp. 149-155 ◽  
Author(s):  
Anna Förg ◽  
Jakob Hein ◽  
Katharina Volkmar ◽  
Martin Winter ◽  
Christoph Richter ◽  
...  
Keyword(s):  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Controlled Trial ◽  
Alcohol Withdrawal Syndrome ◽  
Efficacy And Safety

Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome

2020 ◽  
pp. 001857872093175
Author(s):  
Valentin Yurievich Skryabin ◽  
Mikhail Zastrozhin ◽  
Marco Torrado ◽  
Elena Grishina ◽  
Kristina Ryzhikova ◽  
...  
Keyword(s):  
Steady State ◽  
Genetic Polymorphisms ◽  
Adverse Drug Reactions ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Alcohol Withdrawal Syndrome ◽  
Efficacy And Safety ◽  
Drug Reactions ◽  
Steady State Concentration ◽  
State Concentration

Background: Diazepam is one of the most widely prescribed tranquilizers for the therapy of alcohol withdrawal syndrome (AWS), which includes the symptoms of anxiety, fear, and emotional tension. However, diazepam therapy often turns out to be ineffective, and some patients experience dose-dependent adverse drug reactions, reducing the efficacy of therapy. Aim: The purpose of our study was to investigate the effects of CYP2C19*17 genetic polymorphisms on the steady-state concentration of diazepam in patients with AWS. Materials and Methods: The study was conducted on 50 Russian male patients suffering from the AWS. For the therapy of psychomotor agitation, anxiety, fear, and emotional tension, patients received diazepam in injections at a dosage of 30.0 mg/day for 5 days. Genotyping was performed by real-time polymerase chain reaction. The efficacy and safety assessment was performed using psychometric scales and scales for assessing the severity of adverse drug reactions. Therapeutic drug monitoring (TDM) was performed using the high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS) method. Results: Based on the results of the study, we revealed the differences in the efficacy of therapy in patients with different CYP2C19 − 806C>T genotypes: (*1/*1) −12.0 [−15.0; −8.0], (*1/*17+*17/*17) −7.0 [−14.0; −5.0], P < .001, as well as the results of TDM: ( CC) 250.70 [213.34; 308.53] ng/mL (*1/*17+*17/*17) 89.12 [53.26; 178.07] ng/mL, P < .001. Conclusion: Thus, our study enrolling 50 patients with AWS, showed the effects of CYP2C19*17 genetic polymorphisms on the efficacy and safety rates of diazepam. Furthermore, we revealed the statistically significant difference in the levels of plasma steady-state concentrations of diazepam in patients carrying different genotypes.

How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Valentin Yu Skryabin ◽  
Mikhail S. Zastrozhin ◽  
Marco V. Torrado ◽  
Elena A. Grishina ◽  
Kristina A. Ryzhikova ◽  
...  
Keyword(s):  
Genetic Polymorphisms ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Safety Assessment ◽  
Alcohol Withdrawal Syndrome ◽  
Efficacy And Safety ◽  
Psychometric Scales ◽  
Therapy Efficacy ◽  
Scale Scores ◽  
Male Patients

Abstract Background Diazepam is one of the most commonly prescribed tranquilizers for therapy of alcohol withdrawal syndrome (AWS). Despite its popularity, there is currently no precise information on the effect of genetic polymorphisms on its efficacy and safety. The objective of our study was to investigate the effect of CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the efficacy and safety of diazepam in patients with AWS. Methods The study was conducted on 30 Russian male patients suffering from the AWS who received diazepam in injections at a dosage of 30.0 mg/day for 5 days. The efficacy and safety assessment was performed using psychometric scales and scales for assessing the severity of adverse drug reactions. Results Based on the results of the study, we revealed the differences in the efficacy of therapy in patients with different CYP2C19 681G>A (CYP2C19*2, rs4244285) genotypes: (CYP2C19*1/*1) −8.5 [−15.0; −5.0], (CYP2C19*1/*2 and CYP2C19*2/*2) −12.0 [−13.0; −9.0], p = 0.021. The UKU scale scores, which were used to evaluate the safety of therapy, were also different: (CYP2C19*1/*1) 7.0 [6.0; 12.0], (CYP2C19*1/*2 and CYP2C19*2/*2) 9.5 [8.0; 11.0], p = 0.009. Patients carrying different CYP2C19 –806C>T (CYP2C19*17, rs12248560) genotypes also demonstrated differences in therapy efficacy and safety rates. Conclusions Thus, the effects of CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the efficacy of diazepam were demonstrated.

scholarly journals The relationship between the CYP2C19*17 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome

2020 ◽  
Vol 18 (4) ◽  
pp. 119-126
Author(s):  
V. Yu. Skryabin ◽  
M. S. Zastrozhin ◽  
E. A. Grishina ◽  
K. A. Ryzhikova ◽  
V. V. Shipitsyn ◽  
...  
Keyword(s):  
Genetic Polymorphism ◽  
Adverse Drug Reactions ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Alcohol Withdrawal Syndrome ◽  
Efficacy And Safety ◽  
Drug Reactions ◽  
Specific Hybridization ◽  
Allele Specific ◽  
The Relationship

The aim of our study was to study the relationship between the CYP2C19 genetic polymorphism and the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome in order to develop algorithms for optimizing the therapy of diazepam to reduce the risk of dose-dependent adverse drug reactions and pharmacoresistance.Materials and methods. The study was conducted on 30 Russian male patients suffering from alcohol withdrawal syndrome. For the treatment of anxiety, fear and emotional tension, patients received diazepam in injections at a dosage of 30,0 mg / day for 5 days. Genotyping was performed by real-time polymerase chain reaction with allele-specific hybridization. The efficacy and safety assessment was performed using psychometric scales and scales for assessing the severity of adverse drug reactions: the Clinical Institute Withdrawal Assessment for Alcohol scale, the visual-analogue scale of the craving for alcohol, and the side-effect scale.Results. Based on the results of the study, we revealed the differences in the efficacy of therapy in patients with different CYP2C19 -806C>T genotypes: (CC) –12,0 [–15,0; –8,0], (CT + TT) –7.0 [–14,0; –5,0], p = 0,001. The scores on the UKU scale, which was used to evaluate the safety of therapy, were also different: (CC) 8,0 [6,0; 12,0], (CT + TT) 6,0 [6,0; 12,0], p = 0,006.Conclusion. The relationships between the CYP2C19 genetic polymorphism and the efficacy and safety of diazepam were demonstrated. This should be taken into consideration when prescribing this drug to such patients in order to reduce the risk of adverse drug reactions and pharmacoresistance. 

Sign in / Sign up

Export Citation Format

Share Document